LIRA group had liver fat content reduction by 44%, VAT by 18%, and the decreased prevalence of NAFLD by 66%. Also, SHBG levels increased, and free testosterone decreased in the LIRA group / LIRA had significant weight loss compared to placebo. This evidence concerns the gene SHBG and metabolic dysfunction-associated steatotic liver disease.